• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

α-Bromo-5,6,7,8-tetrahydro-1-naphthalenepropanoic Acid Methyl Ester (CAS No. 1282589-52-9): A Key Intermediate in Modern Pharmaceutical Synthesis

The compound α-Bromo-5,6,7,8-tetrahydro-1-naphthalenepropanoic Acid Methyl Ester, identified by its CAS number 1282589-52-9, represents a significant intermediate in the realm of pharmaceutical synthesis. This molecule, characterized by its brominated naphthalene core and ester-functionalized side chain, has garnered attention due to its versatile applications in the development of bioactive molecules.

In recent years, the demand for sophisticated intermediates in drug discovery has surged, driven by the need for more efficient and targeted therapeutic agents. The α-Bromo-5,6,7,8-tetrahydro-1-naphthalenepropanoic Acid Methyl Ester stands out as a crucial building block for synthesizing complex pharmacophores. Its structural features make it particularly useful in constructing molecules with potential therapeutic effects across various disease spectra.

The bromine substituent at the α-position of the naphthalene ring provides a reactive site for further functionalization via cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These reactions are pivotal in forming carbon-carbon bonds, a fundamental requirement for constructing intricate molecular architectures. The presence of the ester group also offers opportunities for hydrolysis or transesterification, allowing for further derivatization to suit specific pharmacological needs.

Recent advancements in medicinal chemistry have highlighted the importance of heterocyclic compounds in drug design. The naphthalene scaffold, as seen in α-Bromo-5,6,7,8-tetrahydro-1-naphthalenepropanoic Acid Methyl Ester, is known for its ability to enhance binding affinity and selectivity due to its rigid planar structure and aromaticity. This has led to its incorporation in numerous drug candidates targeting neurological disorders, cancer, and infectious diseases.

The pharmaceutical industry has increasingly leveraged this compound in the synthesis of kinase inhibitors, which are critical in oncology treatments. Kinase enzymes play a pivotal role in cell signaling pathways, and their inhibition can disrupt tumor growth and proliferation. The brominated naphthalene moiety in α-Bromo-5,6,7,8-tetrahydro-1-naphthalenepropanoic Acid Methyl Ester allows for precise modifications that can optimize binding interactions with target kinases.

In addition to its role in oncology research, this compound has been explored in the development of anti-inflammatory agents. Inflammatory pathways are dysregulated in various chronic diseases, making them attractive targets for therapeutic intervention. The structural versatility of α-Bromo-5,6,7,8-tetrahydro-1-naphthalenepropanoic Acid Methyl Ester enables chemists to design molecules that can modulate inflammatory responses effectively.

The synthesis of this compound typically involves multi-step organic transformations starting from commercially available precursors. Key steps include bromination of a naphthalene derivative followed by esterification with methyl propanoate under controlled conditions. Advances in synthetic methodologies have improved the yield and purity of this intermediate, making it more accessible for large-scale applications.

The growing interest in green chemistry has also influenced the synthesis of α-Bromo-5,6,7,8-tetrahydro-1-naphthalenepropanoic Acid Methyl Ester. Researchers are increasingly adopting solvent-free conditions and catalytic systems that minimize waste and energy consumption. Such innovations align with global efforts to promote sustainable practices in pharmaceutical manufacturing.

In conclusion, the compound α-Bromo-5,6,7,8-tetrahydro-1-naphthalenepropanoic Acid Methyl Ester (CAS No. 1282589-52-9) is a vital intermediate with broad applications in pharmaceutical synthesis. Its unique structural features make it an invaluable tool for developing novel therapeutics targeting diverse diseases. As research continues to uncover new applications and synthetic strategies, this compound is poised to remain a cornerstone of modern drug discovery efforts.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)